Evidence map›Paper›PMID 39285370›Full record

ArticleBMC pulmonary medicine2024

A novel pulmonary fibrosis NOD/SCID murine model with natural aging.

Zhaoxia Ma, Lihua Qiu, Jianxiu Sun, Zhen Wu, Shu Liang, Yunhui Zhao, Jinmei Yang, Shijun Yue, Min Hu, Yanjiao Li

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Regulatory Roles for SIRT1 in Aging and Immunosenescence.Results and problems in cell differentiation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhaoxia Ma *Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Lihua Qiu *Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Jianxiu SunYunnan Jici Institute for Regenerative Medicine Co., Ltd, Kunming, Yunnan, 650101, China.
Zhen WuShenzhen Zhendejici Pharmaceutical Research and Development Co., Ltd, Shenzhen, 518048, Guangdong, China.
Shu LiangYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Yunhui ZhaoYunnan Jici Institute for Regenerative Medicine Co., Ltd, Kunming, Yunnan, 650101, China.
Jinmei YangYunnan Jici Institute for Regenerative Medicine Co., Ltd, Kunming, Yunnan, 650101, China.
Shijun YueYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Min HuYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China. huminynkm@163.com.
Yanjiao LiYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China. YanjiaoLi1688@126.com.

Funding

The Role of Immunoproteasome Function in Alzheimer's Disease and AgingRF1AG070075 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MYEKU, NATURA · 2021 to 2021
$2.3M
The Role of Immunoproteasome Function in Alzheimer's Disease and AgingR01AG070075 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MYEKU, NATURA · 2024 to 2025
$1.5M
NIA NIH HHS R01 AG070075NIA NIH HHS RF1 AG070075Talent Research Project of Kunming University YJL23012Yunnan Key Laboratory of Basic Research for Bone and Joint Diseases 202205AG070075
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is an age-related disease severely affecting life quality with its prevalence rising as the population ages, yet there is still no effective treatment available. Cell therapy has emerged as a promising option for IPF, however, the absence of mature and stable animal models for IPF immunodeficiency hampers preclinical evaluations of human cell therapies, primarily due to rapid immune clearance of administered cells. This study aims to establish a reliable pulmonary fibrosis (PF) model in immunodeficient mice that supports autologous cell therapy and to investigate underlying mechanism.

methodsWe utilized thirty 5-week-old male NOD/SCID mice, categorizing them into three age groups: 12weeks, 32 weeks and 43 weeks, with 6 mice euthanized randomly from each cohort for lung tissue analysis. We assessed fibrosis using HE staining, Masson's trichrome staining, α-SMA immunohistochemistry and hydroxyproline content measurement. Further, β-galactosidase staining and gene expression analysis of MMP9, TGF-β1, TNF-α, IL-1β, IL-6, IL-8, SOD1, SOD2, NRF2, SIRT1, and SIRT3 were performed. ELISA was employed to quantify protein levels of TNF-α, TGF-β1, and IL-8.

resultsWhen comparing lung tissues from 32-week-old and 43-week-old mice to those from 12-week-old mice, we noted a marked increase in inflammatory infiltration, fibrosis severity, and hydroxyproline content, alongside elevated expression levels of α-SMA and MMP9. Notably, the degree of fibrosis intensified with age. Additionally, β-galactosidase staining became more pronounced in older mice. Quantitative PCR analyses revealed age-related, increases in the expression of senescence markers (GLB1, P16, P21), and proinflammatory genes (TGF-β1, TNF-α, IL-1β, IL-6, and IL-8). Conversely, the expression of anti-oxidative stress-related genes (SOD1, SOD2, NRF2, SIRT1, and SIRT3) declined, showing statistically significant differences (*P < 0.05, **P < 0.01, ***P < 0.001). ELISA results corroborated these findings, indicating a progressive rise in the protein levels of TGF-β1, TNF-α, and IL-8 as the mice aged.

conclusionsThe findings suggest that NOD/SCID mice aged 32 weeks and 43 weeks effectively model pulmonary fibrosis in an elderly context, with the disease pathogenesis likely driven by age-associated inflammation and oxidative stress.

Indexed as

AgingDisease Models, AnimalMice, Inbred NODMice, SCIDSirtuin 1ActinsAnimalsHydroxyprolineIdiopathic Pulmonary FibrosisInterleukin-1betaInterleukin-6Interleukin-8LungMaleMatrix Metalloproteinase 9MiceActinsHydroxyprolineInterleukin-1betaInterleukin-6Interleukin-8Matrix Metalloproteinase 9Mmp9 protein, mouseNfe2l2 protein, mouseNF-E2-Related Factor 2Sirt1 protein, mouseSirtuin 1Sirtuin 3Superoxide DismutaseSuperoxide Dismutase-1Superoxide Dismutase 2Transforming Growth Factor beta1Tumor Necrosis Factor-alphaNatural agingNOD/SCID micePulmonary fibrosis model

Identifiers

PMID39285370
PMCPMC11406766

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.